Integrated clinical-radiogenomic screening

1 paper1 finding

In silico1

Associations

1

BRCA-related cancer

downin silico1−24%

1 study

Integrated clinical-radiogenomic screening lowers the risk of BRCA-related cancer in silico (-23.7%).
“reduces the rate of BRCA-related cancers by 23.7%, generating over a 62-year observation period a cost increase by 2.51 €/Year/Person.”
In silico62-year
A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study)
Scientific reports9 Jan 2024

More on BRCA-related cancer

Latest

Scientific Reports10 Jan

A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study)

Computational studyBiomarkers